IDEAYA Biosciences, Inc. (IDYA) stock
IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/303% above fair value
$27.40−2.96 (-9.75%)
Close on Nov 17, 2026Market cap $2.64BP/E –Yield –
IDEAYA Biosciences total assets
Total assets on the balance sheet at the end of each period.
IDEAYA Biosciences's total assets was $1.31B at Jun 30, 2026. For fiscal 2025 it was $1.11B, down 1.3% from the year before. The highest annual figure on record is $1.12B in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11B | -1.3% |
| FY2024 | Dec 31, 2024 | $1.12B | +73.1% |
| FY2023 | Dec 31, 2023 | $649.32M | +67.4% |
| FY2022 | Dec 31, 2022 | $387.97M | +1.7% |
| FY2021 | Dec 31, 2021 | $381.35M | +27.9% |
| FY2020 | Dec 31, 2020 | $298.27M | +164.0% |
| FY2019 | Dec 31, 2019 | $113.00M | +17.0% |
| FY2018 | Dec 31, 2018 | $96.54M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.31B | +25.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.03B | -6.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.11B | -1.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.19B | -4.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.04B | +6.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.10B | +14.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.12B | +73.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.24B | +132.6% |
| Q2 FY2024 | Jun 30, 2024 | $973.66M | +84.6% |
| Q1 FY2024 | Mar 31, 2024 | $961.53M | +163.6% |
| Q4 FY2023 | Dec 31, 2023 | $649.32M | +67.4% |
| Q3 FY2023 | Sep 30, 2023 | $532.94M | +29.7% |
| Q2 FY2023 | Jun 30, 2023 | $527.56M | +56.1% |
| Q1 FY2023 | Mar 31, 2023 | $364.75M | +1.6% |
| Q4 FY2022 | Dec 31, 2022 | $387.97M | +1.7% |
| Q3 FY2022 | Sep 30, 2022 | $410.91M | +2.9% |
| Q2 FY2022 | Jun 30, 2022 | $338.01M | +2.9% |
| Q1 FY2022 | Mar 31, 2022 | $358.87M | +10.0% |
| Q4 FY2021 | Dec 31, 2021 | $381.35M | +27.9% |
| Q3 FY2021 | Sep 30, 2021 | $399.44M | +32.5% |
| Q2 FY2021 | Jun 30, 2021 | $328.40M | +78.0% |
| Q1 FY2021 | Mar 31, 2021 | $326.10M | +220.4% |
| Q4 FY2020 | Dec 31, 2020 | $298.27M | +164.0% |
| Q3 FY2020 | Sep 30, 2020 | $301.38M | +146.4% |
| Q2 FY2020 | Jun 30, 2020 | $184.51M | +38.4% |
| Q1 FY2020 | Mar 31, 2020 | $101.79M | +5.4% |
| Q4 FY2019 | Dec 31, 2019 | $113.00M | – |
| Q3 FY2019 | Sep 30, 2019 | $122.33M | – |
| Q2 FY2019 | Jun 30, 2019 | $133.36M | – |
| Q4 FY2018 | Dec 31, 2018 | $96.54M | – |
See a number that looks wrong?